Lv4
452 积分 2026-03-24 加入
Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
5天前
已完结
The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy
5天前
已完结
P1.01-052 Patient-Reported Outcomes (PROs) in OAK: a Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
5天前
已完结
Pigment cell & melanoma research
5天前
已完结
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
5天前
已完结
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
5天前
已完结
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
5天前
已完结
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
5天前
已完结
Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors
6天前
已完结
HEALTHRELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCEDSTAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL
6天前
已完结
皖公网安备34019202002308
